ストックスクリーナーアプリを入手
7.33
4.42%
0.31
アフターアワーズ：
7.33
前日終値:
$7.02
開ける：
$7.06
24時間の取引高:
913.02K
Relative Volume:
0.74
時価総額：
$683.26M
収益：
$823.60M
当期純損益:
$-116.00M
株価収益率:
-5.6385
EPS:
-1.3
ネットキャッシュフロー:
$-107.30M
1週間 パフォーマンス:
-3.55%
1か月 パフォーマンス:
-10.39%
6か月 パフォーマンス:
+50.20%
1年 パフォーマンス:
-54.84%
1日の値動き範囲:
$7.02
$7.349
1週間の範囲:
$6.925
$7.72
52週間の値動き範囲:
$3.76
$16.83
Myriad Genetics Inc Stock (MYGN) Company Profile
名前
Myriad Genetics Inc
セクター
電話
801-584-3600
住所
322 NORTH 2200 WEST, SALT LAKE CITY, UT
MYGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
7.33 | 654.36M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
580.45 | 218.05B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
228.46 | 160.05B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
725.93 | 58.51B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
149.26 | 42.12B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
227.24 | 38.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-21 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 開始されました | Craig Hallum | Buy |
| 2024-12-10 | 開始されました | UBS | Neutral |
| 2024-12-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Underperform |
| 2024-05-08 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 再開されました | Piper Sandler | Neutral |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Underweight |
| 2023-05-23 | アップグレード | Goldman | Sell → Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 開始されました | Stephens | Equal-Weight |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Sell |
| 2019-09-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-07-29 | ダウングレード | Needham | Strong Buy → Hold |
| 2019-07-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-03-12 | 繰り返されました | Needham | Strong Buy |
| 2019-01-03 | 開始されました | Needham | Strong Buy |
| 2018-11-30 | アップグレード | Goldman | Sell → Neutral |
| 2018-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 開始されました | Goldman | Sell |
| 2018-01-22 | 繰り返されました | Barclays | Equal Weight |
| 2018-01-05 | 開始されました | BTIG Research | Buy |
| 2017-10-02 | 再開されました | Leerink Partners | Mkt Perform |
| 2017-08-09 | 繰り返されました | Barclays | Equal Weight |
| 2017-02-08 | アップグレード | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 開始されました | Deutsche Bank | Sell |
| 2016-10-10 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
すべてを表示
Myriad Genetics Inc (MYGN) 最新ニュース
Upcoming Virtual Meeting on December 11 Hosted by Craig-Hallum f - GuruFocus
Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report? - Yahoo Finance
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial - GlobeNewswire Inc.
1 Healthcare Stock with Promising Prospects and 2 We Question - Markets Financial Content
How Myriad Genetics Inc. stock benefits from strong dollarTrade Risk Assessment & Low Drawdown Investment Ideas - Newser
Why Myriad Genetics Inc. stock appeals to analystsJuly 2025 Retail & Smart Allocation Stock Tips - Newser
Can Myriad Genetics Inc. stock continue upward trendDip Buying & High Accuracy Swing Entry Alerts - Newser
Why Myriad Genetics (MYGN) Stock Is Trading Lower Today - Finviz
How Recent Developments Are Shaping the Myriad Genetics Investment Story - Yahoo Finance
UBS Initiates Coverage of Myriad Genetics (MYGN) with Neutral Recommendation - MSN
Will Myriad Genetics Inc. stock return to pre crisis levelsJuly 2025 Outlook & Breakout Confirmation Trade Signals - BỘ NỘI VỤ
Will Myriad Genetics Inc. stock attract more institutional investorsPortfolio Growth Summary & Real-Time Buy Signal Notifications - BỘ NỘI VỤ
Myriad Genetics, Inc. (MYGN) Stock Forecasts - Yahoo Finance
How Myriad Genetics achieved fast, accurate, and cost-efficient document processing using the AWS open-source Generative AI Intelligent Document Processing Accelerator - Amazon Web Services (AWS)
Earnings Recap: Can Myriad Genetics Inc. stock double in next 5 yearsTake Profit & Free Safe Entry Trade Signal Reports - BỘ NỘI VỤ
Myriad Genetics, Neogen, ICU Medical, HCA Healthcare, and Universal Health Services Stocks Trade Up, What You Need To Know - MSN
Clairity, Myriad Genetics, MagView partner on breast cancer risk tools By Investing.com - Investing.com Nigeria
Myriad Genetics partners to use AI to measure breast cancer risk - Seeking Alpha
Clairity, Myriad Genetics, MagView partner on breast cancer risk tools - Investing.com
Clairity, Myriad Genetics, and MagView Collaborate to Enhance Breast Cancer Risk Assessment Tool - Quiver Quantitative
Clairity, Myriad Genetics, Inc. and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health - MarketScreener
Myriad Genetics (NASDAQ: MYGN), Clairity and MagView launch AI breast risk platform - Stock Titan
Myriad Genetics joins Forbes list of America's dream employers for 2026 - Traders Union
Myriad Genetics Inc Stock Analysis and ForecastSmall Cap Stock Opportunities & Low Entry Cost Capital - earlytimes.in
Myriad Genetics Q3 2025 Earnings Preview - MSN
Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know - Yahoo Finance
Can Myriad Genetics Inc. stock sustain market leadershipMarket Activity Report & Real-Time Volume Spike Alerts - newser.com
Is Myriad Genetics Inc. (MYD) stock nearing a technical breakout2025 Key Highlights & Detailed Earnings Play Strategies - newser.com
Will Myriad Genetics Inc. stock benefit from sector rotationJuly 2025 Technicals & Entry Point Strategy Guides - newser.com
Why analysts upgrade Myriad Genetics Inc. stockJuly 2025 Big Picture & Technical Pattern Recognition Alerts - newser.com
Is Myriad Genetics Inc. (MYD) stock a buy on weaknessEarnings Growth Report & High Accuracy Swing Trade Signals - newser.com
Is Myriad Genetics Inc. (MYD) stock attractive for growth fundsMarket Activity Report & Growth Oriented Trade Recommendations - newser.com
How to use a screener to detect Myriad Genetics Inc. breakoutsPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com
How Myriad Genetics Inc. (MYD) stock gains from tech spendingQuarterly Investment Review & Weekly Hot Stock Watchlists - newser.com
Is Myriad Genetics Inc. still worth holding after the dipGold Moves & Low Drawdown Momentum Trade Ideas - newser.com
What’s the recovery path for long term holders of Myriad Genetics Inc.2025 AllTime Highs & Weekly Top Gainers Trade List - newser.com
Will Myriad Genetics Inc. (MYD) stock gain from lower interest ratesBond Market & Real-Time Stock Movement Alerts - newser.com
How Myriad Genetics Inc. (MYD) stock moves in volatile trading sessionsDay Trade & Safe Capital Preservation Plans - newser.com
What earnings revisions data tells us about Myriad Genetics Inc.Market Risk Report & Long-Term Growth Stock Strategies - newser.com
Myriad Genetics Inc (MYGN) 財務データ
収益
当期純利益
現金流量
EPS
0.03%
0.06%
大文字化:
|
ボリューム (24 時間):